Clinical development of novel therapeutics for castration‐resistant prostate cancer
Galsky M, Small A, Tsao C, Oh W. Clinical development of novel therapeutics for castration‐resistant prostate cancer. CA A Cancer Journal For Clinicians 2012, 62: 299-308. PMID: 22535487, DOI: 10.3322/caac.21141.Peer-Reviewed Original ResearchMeSH KeywordsAndrostenesAndrostenolsAnilidesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzamidesCancer VaccinesCastrationClinical Trials as TopicDenosumabDrug Therapy, CombinationHumansMaleNitrilesPhenylthiohydantoinProstate-Specific AntigenProstatic NeoplasmsPyridinesRadiopharmaceuticalsRadiumRANK LigandReceptor Protein-Tyrosine KinasesTaxoidsTissue ExtractsConceptsCastration-resistant prostate cancerProstate cancerPathogenesis of castration-resistant prostate cancerTreatment of castration-resistant prostate cancerTreatment of prostate cancerCastration-resistant diseaseUS Food and Drug AdministrationClinical development of novel therapeuticsFood and Drug AdministrationDevelopment of novel therapeuticsClinical developmentRandomized trialsClinical investigationDrug AdministrationNovel therapeuticsCancerTrial designDrugDrug developmentDiseaseTrialsTreatmentTherapyPathogenesisEndpoint
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply